A post-recurrence survival‑predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence

  • Authors:
    • Kosuke Yoshida
    • Hiroaki Kajiyama
    • Fumi Utsumi
    • Kaoru Niimi
    • Jun Sakata
    • Shiro Suzuki
    • Kiyosumi Shibata
    • Fumitaka Kikkawa
  • View Affiliations

  • Published online on: December 8, 2017     https://doi.org/10.3892/mco.2017.1530
  • Pages:281-285
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

The aim of the present study was to estimate the post-recurrence survival (PRS) of patients with relapsed uterine cervical cancer (RUCC). In addition, clinicopathological indicators that influenced PRS were investigated. Between 1998 and 2014, of 740 patients with cervical cancer, 165 patients experienced recurrence (recurrence rate, 22.3%), and 83 patients succumbed to the disease within a median follow‑up of 34.3 months. A total of 151 stage Ib‑IV patients who experienced recurrence after initial treatment for cervical cancer at our institute were analyzed. Uni‑ and multivariate analyses were performed using the Kaplan Meier method, and Cox regression model. The median age was 55 years (range, 20‑88 years). In all, 80 patients succumbed to the disease. The median PRS time of all the patients was 28.4 months. The 1‑, 3‑, and 5‑year PRS rates of patients were 75.1, 41.9, and 32.1%, respectively. In addition, the median survival period in patients who had received surgery as an initial treatment was significantly longer compared with that in patients who had not previously undergone surgery (36.7 vs. 23.3 months, respectively; P=0.0338). Following the univariate analysis, the median PRS in patients with in‑ and out‑field recurrence was 12.6, and 45.9 months, respectively (P<0.0001). Furthermore, in the multivariable analysis, the recurrence site was a significant prognostic indicator of PRS [(In‑field vs. Out‑field); hazard ratio, 2.848; 95% confidence interval, 1.707‑4.738; P<0.0001]. The long‑term clinical outcome of patients with RUCC was poor. In particular, the in‑field recurrence was identified to be associated with poor post‑recurrence oncological outcome in patients with RUCC.

Related Articles

Journal Cover

February 2018
Volume 8 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yoshida, K., Kajiyama, H., Utsumi, F., Niimi, K., Sakata, J., Suzuki, S. ... Kikkawa, F. (2018). A post-recurrence survival‑predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence. Molecular and Clinical Oncology, 8, 281-285. https://doi.org/10.3892/mco.2017.1530
MLA
Yoshida, K., Kajiyama, H., Utsumi, F., Niimi, K., Sakata, J., Suzuki, S., Shibata, K., Kikkawa, F."A post-recurrence survival‑predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence". Molecular and Clinical Oncology 8.2 (2018): 281-285.
Chicago
Yoshida, K., Kajiyama, H., Utsumi, F., Niimi, K., Sakata, J., Suzuki, S., Shibata, K., Kikkawa, F."A post-recurrence survival‑predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence". Molecular and Clinical Oncology 8, no. 2 (2018): 281-285. https://doi.org/10.3892/mco.2017.1530